About us
What we do
Our strategy
Market opportunity
Our team
Our History
Origins – Institute of Cancer Therapeutics (ICT) Bradford
Pipeline
Our products
For patients
Partnering
Our partnerships
Investors
Overview
Why invest?
IPO materials
Regulatory news
Results, Reports and Presentations
Research Notes
Email alerts
Share price and tools
Financial calendar
Shareholder information
Investor and Advisor contacts
AQSE Growth Market Rule 4.14
Corporate Governance
Company Contact Details
News & media
News
Press Coverage
Scientific Publications
Contact Us
Sustainability
Share price
INC 05.25 GBp
About us
What we do
Our strategy
Market opportunity
Our team
Board of Directors
Senior Management
Advisors and Founders
Our History
Origins – Institute of Cancer Therapeutics (ICT) Bradford
Pipeline
Our products
For patients
Partnering
Our partnerships
Investors
Overview
Why invest?
IPO materials
Regulatory news
Results, Reports and Presentations
Research Notes
Email alerts
Share price and tools
Share price chart
Detailed share price
Financial calendar
Shareholder information
Shareholder Information
AGM
GM
Analyst coverage
Investor and Advisor contacts
AQSE Growth Market Rule 4.14
Corporate Governance
Corporate Governance Report
QCA Corporate Governance Principles
Company Contact Details
News & media
News
Press Coverage
Scientific Publications
Contact Us
Sustainability
Latest from Incanthera
Home
News & media
Latest from Incanthera
Latest from Incanthera
2024
2023
2022
Archive
March 23rd, 2021
Incanthera fundraise oversubscribed as it focuses on Sol deal
View
February 25th, 2021
Commercial Update
View
February 25th, 2021
Incanthera updates market on IPO anniversary
View
December 16th, 2020
Incanthera delighted to discuss year’s success
View
December 14th, 2020
Designation into new Apex market of the Aquis Stock Exchange
View
December 8th, 2020
Interim results for the six months ended 30 September 2020
View
Prev
2
3
4
Next